<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        MBX Biosciences has secured USD 63.5 million in a Series C funding round led by Deep Track Capital. Participation came from new investors Driehaus Capital Management, funds and accounts advised by T. Rowe Price Associates, and existing investors Frazier Life Sciences, OrbiMed, and Wellington Management.
      </p>
    </li>
    <li>
      <p>
        The new funds are expected to support the expansion of the company&rsquo;s clinical development programs in hypoparathyroidism, post-bariatric hypoglycemia, and obesity. The proceeds are expected to support MBX into 2026.
      </p>
    </li>
    <li>
      <p>
        MBX Biosciences is a biopharmaceutical company focused on discovering and developing novel precision peptide therapies for endocrine and metabolic disorders. The company has created its proprietary Precision Endocrine Peptide (PEP) platform to address the key limitations of unmodified and modified peptide therapies, aiming to improve clinical outcomes and simplify patient disease management.
      </p>
    </li>
    <li>
      <p>
        <b>Analyst QuickTime: </b>
        In June 2024, the company launched the Phase II clinical trial of 
        <a href="https://www.hypopara.org/news-events/news/mbx-biosciences-launches-phase-2-drug-trial">
          MBX 2109
        </a>
        ,&nbsp;a parathyroid hormone peptide prodrug, for patients with hypoparathyroidism. The top-line results of the trial are expected in the third quarter of 2025. In addition, 
        <a href="https://www.clinicaltrialsarena.com/news/mbx-biosciences-pbh-trial/">
          MBX 1416
        </a>
        , the company&rsquo;s product candidate for post-bariatric hypoglycemia is currently being evaluated in a Phase I single and multiple ascending dose trial, which is expected to report top-line data in the fourth quarter of 2024. 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.globenewswire.com/news-release/2024/08/05/2924234/0/en/MBX-Biosciences-Raises-63-5-Million-in-Series-C-Financing-to-Advance-Precision-Endocrine-Peptide-PEP-Platform.html">
      Press release
    </a>
  </p>
</div>


Precision Medicine

<div>

 <p>MBX Biosciences has successfully raised USD 63.5 million in a Series C funding round. The leading investor for this round was Deep Track Capital, along with new contributors like Driehaus Capital Management, funds and accounts guided by T. Rowe Price Associates. Previous investors, Frazier Life Sciences, OrbiMed, and Wellington Management also participated in this round.</p>
 <p>These funds are anticipated to significantly assist the expansion of the company’s clinical development programs that are currently researching hypoparathyroidism, post-bariatric hypoglycemia, and obesity. Furthermore, the resources from this round are projected to support the operation and objectives of MBX until the year 2026.</p>
 <p>The company is a biopharmaceutical firm with a specialization in the discovery and advancement of innovative precision peptide solutions for endocrine and metabolic disorders. Their unique feature is the proprietary Precision Endocrine Peptide (PEP) platform, specifically developed to overcome the obstacles posed by both unmodified and chemically altered peptide therapies, with the ultimate objective of enhancing clinical outcomes and simplifying the process of managing patient diseases.</p>
 <p><b>Analyst QuickTime: </b> In the middle of 2024, the company initiated their Phase II clinical trial of <a href="https://www.hypopara.org/news-events/news/mbx-biosciences-launches-phase-2-drug-trial"> MBX 2109 </a> , which is a parathyroid hormone peptide prodrug developed for patients suffering from hypoparathyroidism. They anticipate the preliminary results of this trial to be released in the third quarter of 2025. Likewise, <a href="https://www.clinicaltrialsarena.com/news/mbx-biosciences-pbh-trial/"> MBX 1416 </a> , another product developed by the company for treating post-bariatric hypoglycemia, is currently undergoing evaluations in a Phase I trial. This trial involves both single and multiple ascending dose testing, and the company anticipates to reveal the preliminary data by the end of 2024.</p>

</div>

MBX Biosciences raises USD 63.5 million in Series C funding to support clinical development programs in hypoparathyroidism, post-bariatric hypoglycemia, and obesity

Using real-time data to create dynamic virtual representations of the real world

Digital Twin

<div>
 <p>Slingshot Aerospace, a provider of AI-powered space solutions, has raised USD 30 million in growth capital from Trinity Capital. </p>
 <p>These additional funds are planned to be used to expand operations and support key growth initiatives for the company.</p> 
</div>

Slingshot Aerospace secures USD 30 million in growth capital from Trinity Capital

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 <p>Akselos, a provider of digital twin technology, has launched a new software called Structural Performance Management for FPSO 4.0. The software is designed for Floating Production Storage and Offloading (FPSO) vessels and aims to enhance their operations and longevity.</p>
 <p>The software offers several benefits including a reduction in operating costs, optimal planning for inspections and maintenance, minimal downtime, and faster resolution of structural issues. Utilizing RB-FEA technology, the software produces millimeter-level precision for monitoring structural integrity. It develops a digital twin of the FPSO and has the capability to integrate various data such as inspection, metocean, tank fills, and unloading.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> Akselos has entered partnerships to offer digital twin solutions for FPSOs in the past. Last September, the company partnered with <a href="https:<br>
//sp-edge.com/updates/21998"> Yinson Production and Enauta </a> to deploy Akselos' digital twin technology on the floating vessel Atlanta FPSO in Brazil's Santos Basin.</p>

Akselos introduces software for FPSO monitoring

Clean, congestion-free air travel gets liftoff

Passenger eVTOL Aircraft

<div>
 <p>Vertical Aerospace, a UK-based aerospace and technology company, has completed the first phase of flight testing for its VX4 eVTOL aircraft, though pricing information is yet to be released. The company plans to carry out the next phase of the testing program, which includes thrustborne piloted flights for the prototype, at Cotswold Airport.</p>
 <p>According to the company, pre-orders for up to 1,500 eVTOL aircraft have been placed, valued at approximately USD 6 billion. The orders are from potential customers such as Virgin Atlantic Airways, American Airlines, Japan Airlines, Brazil’s GOL Airlines, and helicopter operator Bristow.</p>
 
</div> <p><b>Analyst QuickTake:<br>
</b> The VX4 prototype was first unveiled in <a href="https:<br>
//sp-edge.com/updates/31652"> July 2024 </a> , with new electric propulsion units that increased the aircraft's power-to-weight ratio by 20% to achieve its target cruise speed of ~240 mph. In <a href="https:<br>
//sp-edge.com/updates/32019"> July 2024 </a> , the company completed VX4's first tethered piloted flight, and in <a href="https:<br>
//sp-edge.com/updates/33502"> September 2024 </a> , Vertical Aerospace partnered with Olsen Actuators and Drives to receive flight control actuation systems for an older VX4 prototype, the VA-1X.</p>

Vertical Aerospace completes first phase of VX4 flight testing

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 <p>Turbine, a company specialising in AI-based biological simulations, has made a significant development in its research partnership with Ono Pharmaceutical. Multiple targets identified through Turbine's Simulated Cell platform, which operates in silico, have been selected by Ono for future development.</p>
 <p>Under the terms of the original agreement, reaching this milestone triggers a payment to Turbine. The company will also provide consultation for Ono during the leading in vitro validation studies of the selected oncology targets at Ono's laboratory facilities. Additional payments could be made to Turbine based on the success of the validation process and ongoing drug development and commercialisation.</p>
 
</div> <p><b>Analyst QuickTake:<br>
</b> The original partnership agreement between Turbine and Ono Pharmaceutical was established in <a href="https:<br>
//www.businesswire.com/news/home/20231024051366/en/Turbine-Establishes-Research-Collaboration-with-Ono-Pharmaceutical-to-Identify-and-Validate-Novel-Oncology-Targets-%C2%A0"> October 2023 </a> to identify and validate novel targets within the oncology domain, a priority area for Ono. Turbine agreed to deploy its Simulated Cell platform for target discovery and to conduct in vitro and in vivo validation of identified targets in return for developmental milestone payments based on the progress of drug development and commercialization by Ono.</p>

Turbine and Ono Pharmaceutical reach developmental milestone in oncology research collaboration

<div>
 
 <p>Digital biology company BioGeometry has partnered with Sino Biological to enhance protein research and development with their AI protein design and recombinant protein production technologies. A combination of GenAI platform and lab experiments will optimize protein design.</p>
 <p>The use of AI models and experimental data integration will improve efficiency, accuracy and reduce project duration time. This will aid in developments in biopharmaceuticals, disease treatment and sustainable development through expanded protein research.</p>
 <p>BioGeometry, based in China, specializes in AI-driven protein design. Its GenAI platform, GeoBiologics, uses geometric deep learning to model and optimize interactions between antigens and antibodies. The platform aids pharmaceutical companies in creating novel antibodies with AI-powered tools for protein molecule design and structure prediction.&nbsp;</p>
 
</div>

Sino Biological and BioGeometry partner to optimize protein design using GenAI technology

<div>

 <p>Sinopia Biosciences, a biotherapeutics company that utilizes AI, has been granted a Phase II SBIR grant of USD 2.2 million from the National Institute of Dental and Craniofacial Research (NIDCR). This funding will be used to speed up its oral mucositis program through directing the discovery and optimization process. Sinopia Biosciences will make use of its Learn And Discover (LEADS) technology along with AI and ML for the discovery and development of drugs.</p>
 <p>The main focus of Sinopia Biosciences is to develop new therapeutics via its unique computational drug discovery platform, LEADS. This platform makes use of high-throughput multi-omics data combined with AI/ML and network biology to identify and prioritize new drug targets and compounds. Aside from that, the company is also developing its lead clinical candidate, SB-0110, for the treatment of Parkinson's disease and levodopa-induced dyskinesia.</p>

</div>

Sinopia Biosciences raises USD 2.2 million in Phase II SBIR grant funding to accelerate oral mucositis program

Retail investors demanding sophisticated passive investment strategies are looking for an edge.

Retail Trading Infrastructure

<div>
 
 <p>The online trading platform eToro, based in Israel, has consented to pay a penalty of USD 1.5 million to resolve SEC allegations of functioning as an unregistered broker and clearing agency for certain cryptocurrencies. </p>
 <p>In accordance to the settlement, eToro will restrict its US customers to trade only Bitcoin, Bitcoin Cash, and Ether on its platform. The activities with other cryptocurrencies offered as securities will be stopped. The platform will give its users the go-ahead to sell other cryptocurrencies 180 days post the SEC's order and liquidate any remainders within 187 days, refunding these proceeds to its customers.</p>
 <p>The SEC regards this settlement as a step towards augmenting investor protection and provides a blueprint for other crypto intermediaries to adhere to the existing regulatory frameworks.</p>
 
</div>

eToro settles for USD 1.5 million with SEC over unregistered trading of certain crypto assets

Longevity Tech

<div>

 <p>Amprion has received a USD 100,000 grant from The ALS Network. The company will use these funds to conduct research to understand the cause of sporadic amyotrophic lateral sclerosis (ALS) and to develop potential therapies. This includes supporting necessary clinical and lab research, as well as the development of lab tests to detect other misfolding proteins connected to ALS pathology.</p>
 <p>The company specializes in diagnostic tests for neurodegenerative diseases, identifying misfolded proteins correlated with illnesses such as Parkinson’s disease, Lewy body dementia (LBD), and Alzheimer’s disease with Lewy bodies. Amprion's flagship product, the SAAmplify-ɑSYN Test, uses a seed amplification assay (SAA) method to recognize misfolded proteins before the disease symptoms become apparent. </p>

</div>

Amprion raises USD 100,000 in research grant funding from ALS Network to support ALS research and therapy development

<div>
 
 <p>Amprion has received a USD 100,000 grant from The ALS Network, formerly known as ALS Golden West, to support its global research initiative. The company will use the grant to research the cause of sporadic amyotrophic lateral sclerosis (ALS) and assist the development of potential therapies and lab tests to detect other misfolding proteins tied to ALS pathology.</p>
 
 <p>The company is known for creating diagnostic tests for neurodegenerative diseases. Their tests identify misfolded proteins like alpha-synuclein, related to diseases including Parkinson’s, Lewy body dementia (LBD), and Alzheimer’s disease with Lewy bodies. Amprion's primary product, the SAAmplify-ɑSYN Test, leverages a seed amplification assay (SAA) to detect misfolded proteins before disease symptoms appear.</p>
  
</div>

<div>
 
 <p>Epitopea has obtained a grant worth approximately USD 658,000 from Innovate UK as part of a GBP 12 million Cancer Therapeutics program. This funding will aid Epitopea's investigation into creating therapeutic vaccines and treatments based on T-cell receptors, which target antigens presented distinctively by stromal cells. Using their CryptoMapTM platform, Epitopea plans to extend its RNA immunotherapies range.</p>
 <p>The biotech company, with operations in the UK and Canada, works on creating innovative cancer immunotherapies. Epitopea targets a unique class of tumor-specific antigens (TSAs), termed Cryptigens. Their proprietary platform, CryptoMap, utilizes immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved TSAs that are expressed arbitrarily. This allows for the development of ready-to-use cancer vaccines and additional immunotherapies.</p>
 
</div>

All Updates

MBX Biosciences raises USD 63.5 million in Series C funding to support clinical development programs in hypoparathyroidism, post-bariatric hypoglycemia, and obesity

Slingshot Aerospace secures USD 30 million in growth capital from Trinity Capital

Akselos introduces software for FPSO monitoring

Vertical Aerospace completes first phase of VX4 flight testing

Turbine and Ono Pharmaceutical reach developmental milestone in oncology research collaboration

Sino Biological and BioGeometry partner to optimize protein design using GenAI technology

Sinopia Biosciences raises USD 2.2 million in Phase II SBIR grant funding to accelerate oral mucositis program

eToro settles for USD 1.5 million with SEC over unregistered trading of certain crypto assets

Amprion raises USD 100,000 in research grant funding from ALS Network to support ALS research and therapy development

Amprion raises USD 100,000 in research grant funding from ALS Network to support ALS research and therapy development

Epitopea raises GBP 500,000 in grant funding to develop vaccines and TCR-based therapies

Precision Medicine

MBX Biosciences raises USD 63.5 million in Series C funding to support clinical development programs in hypoparathyroidism, post-bariatric hypoglycemia, and obesity

Contact us